Showing 571-580 of 5127 results for "".
- Abrocitinib Responses Maintained Through Week 72 in JADE REALhttps://practicaldermatology.com/news/abrocitinib-responses-maintained-through-week-72-in-jade-real/2488053/New research suggests that flexible abrocitinib dosing under conditions designed to simulate clinical practice was associated with improvements through Week 72 among observed patients with moderate-to-severe atopic dermatitis (AD). Researchers for the JADE REAL trial enrolled 312 patients
- Online Team-Based Care Matches In-Person Outcomes for Atopic Dermatitis: Analysishttps://practicaldermatology.com/news/online-team-based-care-matches-in-person-outcomes-for-atopic-dermatitis-analysis/2487582/A team-based connected health (TCH) model delivered online achieved equivalent improvements in atopic dermatitis (AD) severity compared with traditional in-person care, according to results from a randomized clinical trial. T
- Intermittent Daily Isotretinoin Matches Alternate-Day Regimen in Grade 2 Acne Trialhttps://practicaldermatology.com/news/intermittent-daily-isotretinoin-matches-alternate-day-regimen-in-grade-2-acne-trial/2487522/A randomized controlled trial published in the Indian Journal of Medical Research found that an intermittent daily isotretinoin regimen was non-inferior to a continuous alternate-day regimen for the treatment of grade 2 facial acne vulgaris, while also offering lower treatment costs.¹ Rese
- Familial Melanoma Genes Associated With Expanded Spectrum of Malignancieshttps://practicaldermatology.com/news/familial-melanoma-genes-associated-with-expanded-spectrum-of-malignancies/2487300/A new study published in JAMA Dermatology suggests pathogenic variants (PVs) in familial melanoma susceptibility genes are present in up to 0.9% of the general population. Investigators for the
- Early Inflammatory Signals May Precede Alopecia Areata Diagnosishttps://practicaldermatology.com/news/early-inflammatory-signals-may-precede-alopecia-areata-diagnosis/2486446/Data from a new systematic review presented at the 2026 American Academy of Dermatology Annual Meeting indicated a consistently elevated neutrophil-to-lymphocyte ratio (NLR) in alopecia areata (AA).Investigators used data from PubMed, Embase, and Cochrane
- Long-term Upadacitinib Data Show Low Rates of MACE, Malignancyhttps://practicaldermatology.com/news/low-rates-of-mace-malignancy-observed-with-upadacitinib-over-6-years/2486427/Long-term safety data from three phase 3 trials (Measure Up 1, Measure Up 2, and AD Up) provided a 6-year view of upadacitinib in moderate-to-severe atopic dermatitis (AD) stratified across multiple age groups. A total of 2,68
- Review: Dermoscopic Patterns May Improve Differentiation of Acral Melanoma and Nevihttps://practicaldermatology.com/news/review-dermoscopic-patterns-may-improve-differentiation-of-acral-melanoma-and-nevi/2486062/A systematic review and meta-analysis in JAMA Dermatology provides updated evidence on dermoscopic features that differentiate acral lentiginous melanoma (ALM) from benign acral nevi. Investigators searched Embase, P
- South Beach Symposium: Dr. Neal Neal Bhatia Maps a Fragmented but Promising Pipelinehttps://practicaldermatology.com/news/south-beach-symposium-dr-neal-neal-bhatia-maps-a-fragmented-but-promising-pipeline/2485624/At the 2026 South Beach Symposium, Neal Bhatia, MD, FAAD, delivered a wide-ranging and opinionated overview of the current dermatology therapeutic landscape, arguing that Innovation is uneven across disease states and increasi
- Study: Upadacitinib Reduces Inflammation Markers in ADhttps://practicaldermatology.com/news/study-upadacitinib-reduces-inflammation-markers-in-ad/2485380/Upadacitinib (UPA) treatment was associated with significant reductions in biomarkers of systemic inflammation in adults with moderate-to-severe atopic dermatitis (AD), according to a poster presented at Winter Clinical 2026 in Hawaii.
- Smoking, PROs, and Attrition May Skew HS Study Outcomes: Commentaryhttps://practicaldermatology.com/news/smoking-pros-and-attrition-may-skew-hs-study-outcomes/2484927/A letter to the editor published in JAAD provided commentary and presented additional opportunities for further research on adalimumab and the effects of smoking on patient response while treating hidradenitis suppurativa (HS).